Discover how eating too few carbs can influence hormones that affect energy, appetite, metabolism, mood, and menstrual cycles ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Results for 8-week 48 mg Cohort in Phase 1b Trial of DA-1726 ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.

With the advent of oral obesity treatments as an alternative to injections, interest in obesity therapy is intensifying in ...

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

As the new year begins, many are using glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss. While effective, these medications can cause nutritional deficiencies, making dairy a vital ...

Bunnie XO shares her harrowing experience with an experimental weight-loss drug, describing severe depression and suicidal ...

Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body already produces called glucagon-like peptide-1 (GLP-1), which helps regulate ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

New fleet of weight loss drugs are more effective than the current popular obesity medications at trial - One in eight Americans are taking a GLP-1 drug, a recent poll found ...